You are here: Industry Insights > AstraZeneca

News List

AstraZeneca's Lynparza scores limited NICE backing for new first-line maintenance use fiercepharma
July 29, 2019
With competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new recommendation—a couple of caveats notwithstanding.
AstraZeneca's cancer meds Lynparza, Imfinzi cruise toward blockbuster-land fiercepharma
July 28, 2019
AstraZeneca’s oncology portfolio put on another good show, with anti-PD-L1 Imfinzi and Merck & Co.-shared PARP inhibitor Lynparza now on track to cross the blockbuster line for the first time in 2019.
AstraZeneca’s roxadustat reveals positive results against anaemia biospectrumasia
July 28, 2019
AstraZeneca and FibroGen China, a wholly-owned subsidiary of FibroGen Inc., are collaborating on the development and commercialisation of roxadustat in China
AstraZeneca to shell out £12M in severance dispute with workers at former England plant fiercepharma
July 20, 2019
When AstraZeneca sold its Avlon, England plant to CDMO Avara in 2016, it was touted as a lifeline for the drugmaker’s 210 on-site employees who faced termination.
AstraZeneca’s Imfinzi cancer drug secures orphan status in US pharmaceutical-technology
July 17, 2019
The US Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to AstraZeneca’s Imfinzi (durvalumab) in small cell lung cancer (SCLC).
FDA rejects AstraZeneca’s Farxiga treatment europeanpharmaceuticalreview
July 17, 2019
AstraZeneca has been issued with a complete response letter for Farxiga by the FDA meaning that it has rejected the treatment.
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector europeanpharmaceuticalreview
July 05, 2019
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector.
CHMP issues positive opinion for AstraZeneca’s Fasenra Pen pharmaceutical-technology
July 04, 2019
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Fasenra Pen, a pre-filled, single-use auto-injector.
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche fiercepharma
July 04, 2019
After Imfinzi's key non-small cell lung cancer trial failure last year, AstraZeneca has some good news to report in lung cancer. But it's from the much smaller field of small cell lung cancer where Roche’s Tecentriq is a step ahead.
AstraZeneca launches 'Cancer Can Give' movement biospectrumasia
June 28, 2019
In celebration of National Cancer Survivors Day, AstraZeneca, a global, science-led biopharmaceutical company, on 27 June 2019, announced the launch of the ‘Cancer Can Give’ movement aimed at empowering cancer survivors to make a difference in society.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page